Results 101 to 110 of about 4,502 (202)

Aprepitant [PDF]

, 2020
openaire   +1 more source

Targeting Circadian Rhythm Disruption in Glaucoma: PTGDS Mediates Trabecular Meshwork Fibrosis and Is Therapeutically Targeted by Aprepitant. [PDF]

Transl Vis Sci Technol
Yuan H, Che Y, Zhang Y, Cai Z, Ping YT, Wang X, Yang Y.   +6 more
europepmc   +1 more source

Spray-freeze-drying aprepitant with hydroxypropyl cellulose increases nasal bioavailability. [PDF]

Int J Pharm X
Rautenberg A, Bühlbecker P, Kožák J, Chrétien C, Pellequer Y, Wunderling K, Stoyanov E, Pfeifer A, Lamprecht A.   +8 more
europepmc   +1 more source

Structure-Guided Repurposing of Approved Drugs Identifies Aprepitant and Mavorixafor as Putative δ-Opioid Receptor Agonist Candidates. [PDF]

Int J Mol Sci
Buccheri R, Reale C, Coco A, Parenti C, Pasquinucci L, Rescifina A.   +5 more
europepmc   +1 more source

Anti-Inflammatory Evaluation of Pyrazino[2,1-<i>b</i>]quinazoline-3,6-dione Derivatives Inspired by Fiscalin B. [PDF]

Pharmaceuticals (Basel)
Martins MS, Pinto MMM, Almeida IF, Cruz MT, Sousa E.   +4 more
europepmc   +1 more source

Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer. [PDF]

Curr Oncol
Doğan A, Erölmez HN, Akdağ G, Yıldırım S, Sever ÖN.   +4 more
europepmc   +1 more source

Neuropeptide and cytokines expression in long COVID-19 related neuropsychological sequelae: insights into NK1R-mediated neuroinflammation and <i>in silico</i> therapeutic targeting. [PDF]

Front Cell Neurosci
Abdullah M, Naz A, Reznikov LR, Qureshi JA, Hasnain A, Obaid A, Ali A.   +6 more
europepmc   +1 more source

Drug-assisted synthesis of copper nanoparticles and their induction of cuproptosis and necrosis for breast cancer therapy. [PDF]

J Zhejiang Univ Sci B
Wang Y, Gao J, Cheng Y, Pan H, Tang H, Liu C.   +5 more
europepmc   +1 more source

The impact of NK1 receptor antagonist selection on chemotherapy-related adverse events: a retrospective study of adverse events in paclitaxel or nab-paclitaxel and carboplatin combination therapy with fosnetupitant and aprepitant use. [PDF]

Front Pharmacol
Yamaoka K, Kajita S, Kume M, Hirabatake M, Sato Y, Hashida T, Tachikawa R, Muroi N.   +7 more
europepmc   +1 more source

Targeting sirtuin 1/nuclear factor erythroid 2-related factor 2/tumor necrosis factor-α pathway to modulate hepatic ischemia reperfusion-induced injury. [PDF]

World J Hepatol
Kelleni MT, Abdelzaher WY, Adly M, Attya ME, Fawzy MA, Ibrahim MA.   +5 more
europepmc   +1 more source